Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
58.30
+1.22 (2.14%)
At close: May 14, 2026, 4:00 PM EDT
59.00
+0.70 (1.20%)
After-hours: May 14, 2026, 7:40 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,053,556
Profits / Employee
$63,947
Market Cap
6.26B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Apellis Pharmaceuticals | 739 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
CORT News
- 1 day ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 1 day ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 10 days ago - Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright - TheFly
- 13 days ago - Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler - TheFly
- 14 days ago - Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study - TheFly
- 14 days ago - Corcept Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 14 days ago - Corcept Therapeutics reports Q1 EPS (30c), consensus (14c) - TheFly
- 14 days ago - Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M - TheFly